Overview

Methylphenidate Plus GWI-Nutrient Formula as a Treatment for Patients With Gulf War Illness

Status:
Unknown status

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

The Gulf War Synergy Trial will evaluate the safety and efficacy of a currently available medication, methylphenidate (Ritalin®), combined with a GWI Nutrient Formula (K-PAX Synergy) to treat Gulf War Illness (GWI).

Phase:

Phase 2

Details

Lead Sponsor:

K-PAX Pharmaceuticals, Inc.

Collaborator:

VA Palo Alto Health Care System

Treatments:

Methylphenidate